Albany, NY -- (SBWIRE) -- 08/03/2015 -- Colon cancer is a common gastrointestinal tumor whose incidence varies greatly in different countries. In developed countries, colon cancer is only second to lung cancer among malignant cancers. Its incidence decreases every year in the US and the EU but increases remarkably during the past four decades in Japan. According to the statistics published by the Ministry of Health of the People's Republic of China in 2011, 92-170 out of 1 million people suffer from colon cancer, sex ratio for which is 1.2:1. Although the incidence of colon cancer in China is higher than that in developed countries, it has decreased slightly in recent years.

Browse Complete Report with Toc: http://www.marketresearchreports.biz/analysis/302678

Developed by Roche under the trade name of Avastin, bevacizumab injection is the first angiogenesis inhibitor in the world. In Feb.26, 2010, it was approved by CFDA to treat metastatic colorectal cancer. Currently, bevacizumab injections available in China all come from Roche and its subsidiary Genectech. In Jul. 2013, Kanion Pharmaceutical's Establishment of Evaluation System of Traditional Chinese Medicine's Efficacy in Treating Gastrointestinal Inflammatory Disease as well as Jiangsu Hengrui Medicine Co., Ltd's Introduction of Monoclonal Antibody Technology and Development of Bevacizumab have been designated by the Ministry of Science and Technology of the People's Republic of China as Key International S&T Cooperation Projects. In Dec. 2013, phase I clinical trial of the generic drug of bevacizumab co-developed by Huahai Pharmaceutical and Oncobiologics was approved to be conducted in the EU.

Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/302678

Bevacizumab injection develops fast after entering China, sales value reaching CNY 265 million in 2013 despite a slight decline in 2014 and CAGR during the period of 2010-2014 reaching 126.67%. With improvements in living standards and lifestyle changes, obesity rate in China goes up gradually, which increases the risk of colorectal cancer. Hence the vast demand for bevacizumab injection in China. Currently, the market is monopolized by Shanghai Roche Pharmaceutical Co., Ltd that brought in a sales value of CNY 264 million in 2014. As some local enterprises are trying to make generic drugs of bevacizumab injection, the monopoly of Roche is expected to be broken by local products in the next few years.

Browse More Reports Of Therapeutic Area Reports: http://www.marketresearchreports.biz/category/37

Readers can get at least the following information from this report:
market size of bevacizumab in China
competitive landscape of bevacizumab in Chinese market
price of bevacizumab made by different enterprises in China
market outlook of bevacizumab in China
The author suggests the following groups of people purchase this report:
manufacturers of monoclonal antibody
manufacturers of anti-tumor drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service

About MarketResearchReports.biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

To View The Top Related News: http://www.marketresearchreports.biz/articles

Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/